Mr. Charles Divita, III is CEO and Director at Teladoc Health, Inc. since June 2024. He served as Florida Combined Life Insurance Company, Inc. from 2018 to 2024. He had been Executive Vice President of Co...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mala Murthy	Chief Financial Officer	5.6yrs	US$5.94m	0.054% $ 843.4k
Adam Vandervoort	Chief Legal Officer & Secretary	9.9yrs	US$3.54m	0.029% $ 454.9k
Charles Divita	CEO & Director	less than a year	데이터 없음	데이터 없음
George Brooks	Co-Founder	23yrs	데이터 없음	데이터 없음
Joseph Catapano	Senior VP & Chief Accounting Officer	less than a year	데이터 없음	데이터 없음
Nikolaos Nanis	Chief Technology Officer	no data	데이터 없음	0.044% $ 685.5k
Patrick Feeley	Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Stella Sanchez	Chief of Staff to the CEO & Head of Corporate Marketing	less than a year	데이터 없음	데이터 없음
Carlos Nueno	President of International	4yrs	데이터 없음	데이터 없음
Kelly Bliss	President of U.S. Group Health	4yrs	데이터 없음	0.019% $ 293.1k
Alon Matas	President of BetterHelp	4yrs	데이터 없음	데이터 없음
Andy Puterbaugh	President of Hospital & Health Systems	2.8yrs	데이터 없음	데이터 없음

4.0yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 관리: TDOC 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Charles Divita	CEO & Director	less than a year	데이터 없음	데이터 없음
Thomas McKinley	Independent Director	15.2yrs	US$290.00k	0.023% $ 355.3k
David Shedlarz	Independent Director	8.3yrs	US$294.49k	0.0086% $ 134.6k
David Snow	Independent Non-Executive Chairman	10.9yrs	US$332.50k	0.069% $ 1.1m
Sandra Fenwick	Independent Director	4.2yrs	US$280.00k	0.023% $ 367.5k
Kenneth Paulus	Independent Director	7.9yrs	US$285.00k	0% $ 0
Mark Smith	Independent Director	6.3yrs	US$283.00k	0.0049% $ 75.9k
Catherine Jacobson	Independent Director	4.9yrs	US$280.00k	0.012% $ 185.5k
J. Evans	Independent Director	1.3yrs	US$264.69k	0.0029% $ 46.2k

6.3yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: TDOC 의 이사회는 경험(평균 재직 기간 6.3 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/02 03:08
장 마감 주가	2025/01/02 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Teladoc Health, Inc. 43 애널리스트 중 25 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
null null	Argus Research Company
Vikram Kesavabhotla	Baird
Matthew Gillmor	Baird

Teladoc Health 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Chief People Officer notifies of intention to sell stock

Insider notifies of intention to sell stock

Teladoc Health, Inc. Appoints Joseph Catapano as its Senior Vice President and Chief Accounting Officer

Teladoc Health, Inc. Appoints Charles Divita, III as Director

Teladoc Health, Inc., Annual General Meeting, May 23, 2024

Teladoc Health, Inc. Announces Chief Executive Officer Changes

Recent updates

Teladoc: Attractive Valuation, But The Narrative Stalls

Teladoc: Maybe This Goose Isn't Cooked Yet (Rating Upgrade)

Teladoc Health, Inc. (NYSE:TDOC) Surges 40% Yet Its Low P/S Is No Reason For Excitement

Teladoc Health Expands AI Capabilities for Hospitals and Health Systems with Advanced Virtual Sitter Solution

Chief People Officer notifies of intention to sell stock

Teladoc Health, Inc. (NYSE:TDOC) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Is Teladoc Health (NYSE:TDOC) A Risky Investment?

Teladoc Health, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Insider notifies of intention to sell stock

Teladoc: Double-Digit FCF Yield, Possible BetterHelp Transition

Teladoc Health, Inc. (NYSE:TDOC) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Teladoc Health: Some Negative Things, But One Aspect That Makes Me Feel Positive

Teladoc Health, Inc. Appoints Joseph Catapano as its Senior Vice President and Chief Accounting Officer

Teladoc: Prospects Are Ready For Better Health

Consensus EPS estimates fall by 394%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 11% to US$14.45

Teladoc Post Q2 Earnings: Stick A Fork In This Stock - It's Nearly Done (For)

Teladoc's Vital Signs: Why 5x FCF Means Stable Health (Rating Upgrade)

Teladoc Health, Inc. to Report Q2, 2024 Results on Jul 31, 2024

Teladoc Health, Inc.'s (NYSE:TDOC) Revenues Are Not Doing Enough For Some Investors

Teladoc Health, Inc.(NYSE:TDOC) dropped from Russell 1000 Dynamic Index

Teladoc Health: Weight Loss Management Could Help

Teladoc Health, Inc. Releases New Data from Two Studies

Teladoc Health, Inc. Appoints Charles Divita, III as Director

Would Teladoc Health (NYSE:TDOC) Be Better Off With Less Debt?

Teladoc: Stock Likely To Be Range Bound Until Guidance Is Revised Upwards

Robbins Geller Rudman & Dowd LLP Announces Class Action Lawsuit against Teladoc Health, Inc

Teladoc: Huge Execution Problem

Teladoc Health, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 7.5% to US$18.42

Teladoc: Improving Business Trends (Rating Upgrade)

Teladoc Health, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Teladoc Health, Inc., Annual General Meeting, May 23, 2024

Teladoc Health, Inc. Announces Chief Executive Officer Changes

Teladoc: Management Has A Lot To Prove To Gain Investor Confidence

Teladoc Health, Inc.'s (NYSE:TDOC) 25% Dip In Price Shows Sentiment Is Matching Revenues

CEO & Director exercised options and sold US$780k worth of stock

Price target decreased by 9.6% to US$20.84

No longer forecast to breakeven

Teladoc Health, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Teladoc Health: Another Bad Quarter, Another Wave Of Capitulation

No longer forecast to breakeven

Teladoc Health, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Teladoc Health: Weight Management Rescue

Teladoc Health (NYSE:TDOC) Is Carrying A Fair Bit Of Debt

Forecast to breakeven in 2026

Independent Director notifies of intention to sell stock

When Should You Buy Teladoc Health, Inc. (NYSE:TDOC)?

Insufficient new directors

Teladoc Q3: Getting Stronger (Rating Upgrade)

Teladoc Health, Inc.'s (NYSE:TDOC) Intrinsic Value Is Potentially 78% Above Its Share Price

Teladoc Health, Inc. Announces Resignation of Claus T. Jensen, PhD as Chief Innovation Officer Effective December 1, 2023

Insider notifies of intention to sell stock

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations

Teladoc Health, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending December 31, 2023

Teladoc Was Obliterated

Teladoc Health, Inc. to Report Q3, 2023 Results on Oct 24, 2023

Is Teladoc Health (NYSE:TDOC) A Risky Investment?

Teladoc: Broken Growth Story Deteriorates Further (Rating Downgrade)

Teladoc Health, Inc. Appoints Eric Evans to Board of Directors

Teladoc Stock: A Hold Amid New Covid Wave

Teladoc's Technical Decline Hints At A Buying Opportunity

Is There An Opportunity With Teladoc Health, Inc.'s (NYSE:TDOC) 44% Undervaluation?

Buy Teladoc: AI Will Likely Spur Healthcare Deflation